Jefferies maintains buy call on Sun Pharma despite adverse guidance
International brokerage house Jefferies said it is positive about Sun Pharma's strong key fundamentals, though its stock plunged 15 percent Tuesday, a day after the company warned of a deeper cut in bottomline and topline this year due to ongoing integration with Ranbaxy.
Jul 21, 2015, 19:11 PM IST